Logo for LaunchBio Program: Founders CircleLogo for LaunchBio Program: Founders Circle

A peer advisory forum for life science startup founders and C-level executives

  • September 21, 2023
  • 4:00-6:30pm
BioLabs Philadelphia –The Curtis Center

Funding Now

The State of the Biotech Industry in 2023

Program

Join LaunchBio’s Founders Circle event exclusively for Founders and C-level executives of life science startups. This peer advisory forum is facilitated by industry experts and investment professionals. Founders Circle events center on business challenges that all early-stage life science companies face.

Our peer learning environment encourages sharing of experiences and open discussion of innovative strategies for growing, scaling and funding life science startups.

We will be featuring Matias Porras Paniagua from Insight Partners and offering the opportunity for startups to meet 1:1 with him prior to the Founders Circle forum.

Participation is limited and on an invitation-only basis.

Agenda

Ongoing: 1:1 meetings with Insight Partners

4:00pm Check-in and networking

4:30- 5:45pm Panel discussion

5:45 -6:30pm  Refreshments, networking and tours of BioLabs

Light appetizers and refreshments will be served

discussion

Many factors play into the complex funding environment faced by biotech companies seeking financing. Concerns over the inflation reduction act, the looming patent cliff that has big pharma on the hunt for innovation to fill the pipeline and the string of bank failures earlier this year among other industry issues have caused  uncertainty over market stability. The hazy forecast that has defined the biotech funding outlook over the past several quarters has even the most promising start-ups cautious about their next strategic move.

While market conditions have many financiers continuing to tighten up their de-risking strategies, innovation is still in high demand for VC’s and strategics alike. Understanding the inflection points that will resonate with investors and how to streamline operations to keep the capital burn rate down are key to staying afloat in today’s market. Join us for an informative session with funding experts to discuss the state of the life science industry and what start-ups need to know as they pursue their next round of capital.

Speakers

  • Naomi Pintel Baer

    Naomi Baer, Business Development Consultant, Emerging Biotech, MilliporeSigma

    Naomi Pintel Baer is a highly regarded Business Development Consultant at MilliporeSigma where she supports early-stage biopharma companies developing scalable upstream and downstream processes for advancing biologics into the clinic. She has more than 32 years of experience in the industry, including in the areas of research, process development, and QC biomonitoring. She began her career at a molecular biologist at Dupont. She graduated with a BS degree in biology from Saint Joseph’s University.

  • Matias Porras Paniagua

    Matias Porras Paniagua, PhD, Associate, Insight Partners

    Matias Porras Paniagua, PhD is an Associate in the Life Sciences team at Insight Partners. Founded in 1995, Insight Partners is a global investor partnering with high-growth software companies that are driving transformative change in their industries, including AI/ML/DevOps, Cybersecurity, IT Infrastructure, Biotech, Healtech and more. As of February 2022, the closing of the firm's recent fundraise, Fund XII, brings Insight Partners regulatory assets under management to over $75B. Insight’s Bio team invests in seed through Series B startups across different therapeutic modalities and geographies. They primarily focus on technology-enabled opportunities across drug discovery/development, computational & synthetic biology, and genomic medicine.

  • Arda Ural

    Arda Ural, PhD, Americas Industry Markets Leader, Health Sciences and Wellness, EY

    Arda is the EY Americas Industry Markets Leader for Health Sciences and Wellness.Prior to joining EY, he was a Managing Director at a strategy consulting firm for six years, where he led the Life Sciences M&A Practice. Earlier, he worked as a VP of Strategic Marketing and a BU Lead at an American medical technology company. He also served as the SVP Marketing & Sales for a startup biotechnology company which went public.Arda started his career with a pharmaceutical company in Istanbul and subsequently relocated to New York, where he held leadership roles in product commercialization and new product development.

Partners

Tags